Company / Current Assets
Anika Therapeutics, Inc. Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$103.4M
FY2025
5-year range
$103.4M / $169.5M
FY2021-FY2025
Trend
-9.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has declined for 3 consecutive years, from $170M in FY2022 to $103M in FY2025.
Based on SEC 10-K filings.
$103M in FY2025 with a 5-year CAGR of -15.1%.
Declined from $163M to $103M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -15.2%
- 5-Year CAGR
- -15.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- Anika Therapeutics, Inc.'s current assets has declined for 3 consecutive years.
- 5-year CAGR of -15.1%, indicating a declining trend.
- In FY2025, current assets decreased 9.1% year-over-year.
- Peak current assets was recorded in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $103.4M | -9.1% |
| FY2024 | $113.7M | -30.4% |
| FY2023 | $163.3M | -3.7% |
| FY2022 | $169.5M | +0.6% |
| FY2021 | $168.5M | -28.1% |
| FY2020 | $234.3M | +0.0% |
| FY2019 | $234.3M | +15.5% |
| FY2018 | $202.9M | -1.6% |
| FY2017 | $206.3M | +21.1% |
| FY2016 | $170.4M | -3.4% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026